Affordable Access

Access to the full text

Roles of METTL3 in cancer: mechanisms and therapeutic targeting

Authors
  • Zeng, Chengwu1, 2
  • Huang, Wanxu1, 3
  • Li, Yangqiu2
  • Weng, Hengyou1, 4
  • 1 Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, 510005, China , Guangzhou (China)
  • 2 Jinan University, Guangzhou, 510632, China , Guangzhou (China)
  • 3 The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510700, China , Guangzhou (China)
  • 4 Chinese Academy of Sciences, Guangzhou, 510530, China , Guangzhou (China)
Type
Published Article
Journal
Journal of Hematology & Oncology
Publisher
Springer Science and Business Media LLC
Publication Date
Aug 27, 2020
Volume
13
Issue
1
Identifiers
DOI: 10.1186/s13045-020-00951-w
Source
Springer Nature
Keywords
License
Green

Abstract

N6-methyladenosine (m6A) is the most abundant mRNA modification and is catalyzed by the methyltransferase complex, in which methyltransferase-like 3 (METTL3) is the sole catalytic subunit. Accumulating evidence in recent years reveals that METTL3 plays key roles in a variety of cancer types, either dependent or independent on its m6A RNA methyltransferase activity. While the roles of m6A modifications in cancer have been extensively reviewed elsewhere, the critical functions of METTL3 in various types of cancer, as well as the potential targeting of METTL3 as cancer treatment, have not yet been highlighted. Here we summarize our current understanding both on the oncogenic and tumor-suppressive functions of METTL3, as well as the underlying molecular mechanisms. The well-documented protein structure of the METTL3/METTL14 heterodimer provides the basis for potential therapeutic targeting, which is also discussed in this review.

Report this publication

Statistics

Seen <100 times